INT39914

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1982
Last Reported 2010
Negated 1
Speculated 2
Reported most in Abstract
Documents 44
Total Number 46
Disease Relevance 10.04
Pain Relevance 22.00

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

oxidoreductase activity (Cyp1a2) endoplasmic reticulum (Cyp1a2) enzyme binding (Cyp1a2)
response to stress (Cyp1a2)
Anatomy Link Frequency
liver 4
blood 1
plasma 1
HF2 1
1A2 1
Cyp1a2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Potency 9 100.00 Very High Very High Very High
anticonvulsant 3 99.88 Very High Very High Very High
methadone 28 99.80 Very High Very High Very High
Duloxetine 292 99.76 Very High Very High Very High
antidepressant 109 99.72 Very High Very High Very High
fluoxetine 110 99.40 Very High Very High Very High
Paracetamol 69 99.26 Very High Very High Very High
Endep 25 99.24 Very High Very High Very High
agonist 9 98.80 Very High Very High Very High
sSRI 206 98.72 Very High Very High Very High
Disease Link Frequency Relevance Heat
Liver Disease 8 100.00 Very High Very High Very High
Hepatotoxicity 15 99.56 Very High Very High Very High
Diabetes Mellitus 50 99.54 Very High Very High Very High
Poisoning 3 98.16 Very High Very High Very High
Respiratory Failure 1 97.96 Very High Very High Very High
Injury 7 97.72 Very High Very High Very High
Toxicity 14 97.52 Very High Very High Very High
Nicotine Addiction 4 96.84 Very High Very High Very High
Confusion 1 96.84 Very High Very High Very High
Sleep Disorders 30 96.40 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The observed changes indicate an impairment of N-deethylation metabolic pathway in streptozotocin-induced diabetic rats, i.e. a possible decrease in the enzymatic activity of CYP3A2 and CYP1A2.
Spec (possible) Negative_regulation (decrease) of CYP1A2 associated with diabetes mellitus
1) Confidence 0.58 Published 2006 Journal J. Pharm. Pharmacol. Section Abstract Doc Link 16872554 Disease Relevance 0.63 Pain Relevance 0.28
The observed changes indicate an impairment of N-deethylation, i.e. a possible decrease in enzymatic activity of CYP3A2 and CYP1A2, which are the major enzymes catalyzing this reaction.
Spec (possible) Negative_regulation (decrease) of CYP1A2
2) Confidence 0.56 Published 2003 Journal Pol J Pharmacol Section Abstract Doc Link 12926555 Disease Relevance 0.47 Pain Relevance 0.25
Guaiazulene inhibited CYP1A2 activity in rats with or without paracetamol intoxication.
Negative_regulation (inhibited) of CYP1A2 associated with paracetamol and poisoning
3) Confidence 0.56 Published 1997 Journal Arch. Pharm. (Weinheim) Section Abstract Doc Link 9112807 Disease Relevance 0.25 Pain Relevance 0.33
It is found that guaiazulene inhibited considerably CYP1A2 and CYP2B1 and had a weak effect on CYP1A1 in rat hepatic microsomal fractions.
Negative_regulation (inhibited) of CYP1A2
4) Confidence 0.56 Published 1997 Journal Arch. Pharm. (Weinheim) Section Abstract Doc Link 9112807 Disease Relevance 0.24 Pain Relevance 0.33
The administration of PB suppressed CYP1A2 apoprotein levels in CD rats, whereas the drug had no effect on NF rats.
Negative_regulation (suppressed) of CYP1A2
5) Confidence 0.55 Published 2009 Journal J Appl Toxicol Section Abstract Doc Link 18798224 Disease Relevance 0 Pain Relevance 0.57
The serum AST activities corresponding to a 50% decrease of CYP2C 11, CYP2E1, CYP3A2 and CYP1A2 activities were about 710, 780, 1030 and 1300 IU/l, respectively.
Negative_regulation (decrease) of CYP1A2
6) Confidence 0.53 Published 2004 Journal Int J Pharm Section Abstract Doc Link 14706259 Disease Relevance 0.15 Pain Relevance 0.08
Here, a mixture of ketoconazole, isoniazid and caffeine (inhibitor solution), known inhibitors of CYP3A, CYP2E1 and CYP1A2, was investigated for prevention of hepatotoxicity after paracetamol over-dose in rats.
Negative_regulation (inhibitors) of CYP1A2 associated with paracetamol and hepatotoxicity
7) Confidence 0.53 Published 2004 Journal Hum Exp Toxicol Section Abstract Doc Link 15027815 Disease Relevance 0.41 Pain Relevance 0.62
Intraperitoneal administration of 9-hydroxyellipticine, a specific cytochrome P-448 inhibitor, inhibited 3-methylcholanthrene-induced cytochrome P-448 activity (ethoxyresorufin O-deethylase, biphenyl 2-hydroxylase) and formation of the safrole carbene ligand complex with this cytochrome, but did not inhibit phenobarbital-induced cytochrome P-450 activity (ethyl-morphine N-demethylase) or formation of the safrole carbene ligand complex with this cytochrome.
Negative_regulation (inhibitor) of cytochrome P-448 associated with morphine
8) Confidence 0.50 Published 1982 Journal Chem. Biol. Interact. Section Abstract Doc Link 7151231 Disease Relevance 0 Pain Relevance 0.09
Pharmacokinetic studies looked at the interaction between duloxetine and fluvoxamine, a known potent inhibitor of CYP1A2.
Negative_regulation (inhibitor) of CYP1A2 associated with duloxetine
9) Confidence 0.49 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350145 Disease Relevance 0.07 Pain Relevance 0.53
Inhibitors of CYP1A2
Negative_regulation (Inhibitors) of CYP1A2
10) Confidence 0.49 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350145 Disease Relevance 0.08 Pain Relevance 0.51
Additionally, administration of the PPARalpha agonist clofibrate to male rats up-regulated UGT1A1 and UGT1A6 and down-regulated CYP1A2 in the liver.
Negative_regulation (down-regulated) of CYP1A2 in liver associated with agonist
11) Confidence 0.49 Published 2008 Journal Drug Metab. Dispos. Section Abstract Doc Link 17967931 Disease Relevance 0 Pain Relevance 0.29
In contrast, the CYP1A2 protein level was decreased in the HF1 but not HF2 diet group, whereas CYP2E1 and CYP4A protein levels were elevated in the HF2 but not HF1 diet group.
Neg (not) Negative_regulation (decreased) of CYP1A2 in HF2
12) Confidence 0.49 Published 2008 Journal Drug Metab. Dispos. Section Abstract Doc Link 17967931 Disease Relevance 0 Pain Relevance 0.20
We conclude that inhibition of CYP1A2 by fluvoxamine considerably reduces elimination of lidocaine and may increase the risk of lidocaine toxicity.
Negative_regulation (inhibition) of CYP1A2 associated with toxicity and lidocaine
13) Confidence 0.48 Published 2005 Journal Anesth. Analg. Section Abstract Doc Link 15845683 Disease Relevance 0.10 Pain Relevance 0.92
We suggest that this was caused by ciprofloxacin inhibition of CYP1A2 and CYP3A4 activity, two of the cytochrome p450 isozymes involved in the metabolism of methadone.
Negative_regulation (inhibition) of CYP1A2 associated with methadone
14) Confidence 0.48 Published 2000 Journal Lancet Section Abstract Doc Link 11145498 Disease Relevance 0.37 Pain Relevance 0.31
Glutathione and glutathione-S-transferase increased more by growth factors than by pretreatment, but both conditions reduced Cyp1A2 to near zero.
Negative_regulation (reduced) of Cyp1A2
15) Confidence 0.42 Published 2003 Journal Pharmacol. Toxicol. Section Abstract Doc Link 12969438 Disease Relevance 0.32 Pain Relevance 0.61
In summary, CYP1A2 was distinctly inhibited by imipramine and amitriptyline, CYP3A by imipramine and fluoxetine, while other CYP isoenzymes (CYP2B and/or 2E1) by imipramine and fluoxetine.
Negative_regulation (inhibited) of CYP1A2 associated with endep and fluoxetine
16) Confidence 0.42 Published 2001 Journal Pol J Pharmacol Section Abstract Doc Link 11990081 Disease Relevance 0 Pain Relevance 0.81
Ketoconazole was a highly potent inhibitor of N-demethylation, with a mean Ki value of 0.11 +/- 0.013 microM (+/- S.D.), whereas quinidine (up to 50 microM), a CYP2D6 inhibitor, and alpha-naphthoflavone (up to 5 microM), a CYP1A2 inhibitor only at low concentrations, showed no effect.
Negative_regulation (inhibitor) of CYP1A2
17) Confidence 0.42 Published 1995 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 7473143 Disease Relevance 0 Pain Relevance 0.47
So, fluvoxamine (CYP1A2 inhibitor) can cause an increase of blood levels of theophyllin or caffeine, while paroxetine and fluoxetine (CYP2D6 inhibitors) an increase of concentration of TCAs or atypical antipsychotics.
Negative_regulation (inhibitor) of CYP1A2 in blood associated with fluoxetine
18) Confidence 0.40 Published 2008 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2515899 Disease Relevance 0.46 Pain Relevance 0.59
The objectives of this study were (1) to evaluate the effect of liver cirrhosis on the inhibition by fluvoxamine of the metabolic disposition of theophylline, a CYP1A2 substrate with a low-extraction ratio, to assess whether decreased sensitivity to CYP1A2 inhibition in liver disease is a general characteristic of CYP1A2 substrates, regardless of their pharmacokinetic properties, and (2) to investigate the mechanism(s) underlying the effect of liver dysfunction on CYP1A2 inhibition.
Negative_regulation (inhibition) of CYP1A2 in liver associated with liver disease and cirrhosis
19) Confidence 0.39 Published 2006 Journal Clin. Pharmacol. Ther. Section Abstract Doc Link 16678550 Disease Relevance 0.45 Pain Relevance 0.09
The extent of fluvoxamine-lidocaine interaction decreases as liver function worsens, most likely because of the concomitant decrease in the hepatic level of CYP1A2.
Negative_regulation (decrease) of CYP1A2 in liver
20) Confidence 0.39 Published 2004 Journal Clin. Pharmacol. Ther. Section Body Doc Link 14749694 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox